Search hospitals > California > San Francisco

Kaiser Permanente San Francisco

Claim this profile
San Francisco, California 94115
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
262 reported clinical trials
24 medical researchers
Photo of Kaiser Permanente San Francisco in San FranciscoPhoto of Kaiser Permanente San Francisco in San FranciscoPhoto of Kaiser Permanente San Francisco in San Francisco

Summary

Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Adenocarcinoma and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 415 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Andrew Rassi, MD.

Area of expertise

1Cancer
Global Leader
Kaiser Permanente San Francisco has run 69 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Kaiser Permanente San Francisco has run 42 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
Stage II

Top PIs

Clinical Trials running at Kaiser Permanente San Francisco

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Squamous Cell Carcinoma
Melanoma
Cutaneous Melanoma
Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kaiser Permanente San Francisco?
Kaiser Permanente San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Adenocarcinoma and other specialties. Kaiser Permanente San Francisco is involved with conducting 262 clinical trials across 415 conditions. There are 24 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Andrew Rassi, MD.